Inceptionr LLC Makes New $1.61 Million Investment in Edwards Lifesciences Corporation $EW

Key Points

• Inceptionr LLC opened a new position of 20,674 shares in Edwards Lifesciences during Q3, valued at about $1.61 million, and institutional investors now own roughly 79.46% of the company.
• Edwards reported $0.58 EPS (missing estimates by $0.04) and revenue of $1.57 billion (up 13.3% YoY), issued Q1 2026 guidance of $0.70–$0.76 EPS, and carries a MarketBeat consensus of “Moderate Buy” with a $96.14 price target.
• Insiders have been net sellers recently—79,144 shares (~$6.69 million) sold over the past 90 days including a 24,000-share VP sale—and the stock trades around $81.71 with a market cap of $47.46 billion (P/E 44.65).

Inceptionr LLC purchased a new position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 20,674 shares of the medical research company's stock, valued at approximately $1,608,000.

Other hedge funds have also recently modified their holdings of the company. Level Four Advisory Services LLC raised its holdings in Edwards Lifesciences by 3.7% in the 3rd quarter. Level Four Advisory Services LLC now owns 3,301 shares of the medical research company's stock worth $257,000 after purchasing an additional 119 shares during the period. Colonial Trust Co SC grew its holdings in Edwards Lifesciences by 0.4% during the third quarter. Colonial Trust Co SC now owns 32,196 shares of the medical research company's stock valued at $2,504,000 after purchasing an additional 120 shares during the period. Parkside Financial Bank & Trust grew its holdings in Edwards Lifesciences by 9.8% during the second quarter. Parkside Financial Bank & Trust now owns 1,455 shares of the medical research company's stock valued at $114,000 after purchasing an additional 130 shares during the period. Howard Capital Management Inc. increased its position in Edwards Lifesciences by 3.3% in the third quarter. Howard Capital Management Inc. now owns 4,136 shares of the medical research company's stock worth $322,000 after buying an additional 132 shares in the last quarter. Finally, Empirical Finance LLC raised its stake in shares of Edwards Lifesciences by 0.6% in the second quarter. Empirical Finance LLC now owns 21,329 shares of the medical research company's stock worth $1,668,000 after buying an additional 134 shares during the period. Institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Trading Down 2.6%

Shares of EW stock opened at $81.71 on Monday. The company has a current ratio of 3.72, a quick ratio of 3.09 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $47.46 billion, a price-to-earnings ratio of 44.65, a price-to-earnings-growth ratio of 2.13 and a beta of 0.93. Edwards Lifesciences Corporation has a 12-month low of $65.94 and a 12-month high of $87.89. The stock's 50-day moving average price is $82.56 and its 200-day moving average price is $81.47.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing analysts' consensus estimates of $0.62 by ($0.04). Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The firm had revenue of $1.57 billion for the quarter, compared to the consensus estimate of $1.54 billion. During the same period in the previous year, the company posted $0.59 earnings per share. Edwards Lifesciences's quarterly revenue was up 13.3% on a year-over-year basis. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Equities research analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. The Goldman Sachs Group reaffirmed a "buy" rating and set a $95.00 price objective (down from $108.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. UBS Group restated a "neutral" rating and set a $94.00 target price on shares of Edwards Lifesciences in a research note on Wednesday, February 4th. Stifel Nicolaus set a $110.00 price target on shares of Edwards Lifesciences and gave the company a "buy" rating in a report on Tuesday, January 20th. Piper Sandler reiterated an "overweight" rating and issued a $100.00 price target (up from $98.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Finally, Canaccord Genuity Group set a $87.00 price objective on shares of Edwards Lifesciences and gave the stock a "hold" rating in a research note on Wednesday, December 17th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, Edwards Lifesciences currently has an average rating of "Moderate Buy" and a consensus price target of $96.14.

Insider Activity at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 1,019 shares of the business's stock in a transaction on Friday, January 9th. The shares were sold at an average price of $85.70, for a total value of $87,328.30. Following the sale, the vice president owned 22,002 shares in the company, valued at approximately $1,885,571.40. The trade was a 4.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 24,000 shares of the company's stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $83.84, for a total transaction of $2,012,160.00. Following the sale, the vice president directly owned 21,266 shares in the company, valued at approximately $1,782,941.44. The trade was a 53.02% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 79,144 shares of company stock valued at $6,685,688. 0.34% of the stock is owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.